EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Retraction: Rubidium chloride targets Jnk/p38-mediated NF-κB activation to attenuate osteoclastogenesis and facilitate osteoblastogenesis

Frontiers in Pharmacology · 11.11.2026 · 17

DOI: 10.3389/fphar.2026.2021921 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 11.11.2026. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

(2026). Retraction: Rubidium chloride targets Jnk/p38-mediated NF-κB activation to attenuate osteoclastogenesis and facilitate osteoblastogenesis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.2021921

Vancouver

Retraction: Rubidium chloride targets Jnk/p38-mediated NF-κB activation to attenuate osteoclastogenesis and facilitate osteoblastogenesis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.2021921

BibTeX
@article{euvimed2026,
  title = {Retraction: Rubidium chloride targets Jnk/p38-mediated NF-κB activation to attenuate osteoclastogenesis and facilitate osteoblastogenesis},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.2021921}
}
Kostenlos starten →